Series B · Biotech · Barcelona, Spain · Founded 2019 · 11–50 employees
INBRAIN Neuroelectronics is pioneering the world's first intelligent graphene-based brain-computer interface (BCI) platform for neurological treatments. Founded in 2019 as a spin-off from ICN2 and ICREA in Barcelona, the company has achieved significant milestones including FDA Breakthrough Device Designation for its Parkinson's disease treatment and the world's first human implantation of a graphene neural interface. The company raised €46 million in Series B funding in 2024, led by imec.xpand with participation from Merck. Their revolutionary technology uses graphene's unique properties to create ultra-high resolution, bi-directional neural interfaces that can decode brain signals with unprecedented precision, targeting conditions like Parkinson's and epilepsy.